While drugmakers worry about drug spending cuts around the world, they can still take heart from the good old U.S. of A. Companies raised branded drug prices by 13.3%, but it was the cost of specialty meds, such as new hepatitis C drugs, that saw the steepest climb.
Big Pharma is willing to do its part to cut the deficit; it would just like to do it in a way that is less painful than some in Washington are suggesting.
Onyx Pharmaceuticals has staffed up to launch its newly approved Kyprolis drug for multiple myeloma. The company hired a dedicated marketing team of about 100, Xconomy reports, comprising sales reps, oncology nurses and reimbursement specialists.
Employers have drug costs on their minds lately. Balancing the cost of drugs against care has swelled as the key consideration for companies evaluating drug plans in a survey by Express Scripts.
Co-pay discounts may be good for patients and good for branded drugmakers, but they're not so good for the payers in the middle. So says a new study from pharmacy benefits managers, which concluded
Spending more money on drug therapies actually can be thrifty, at least for Medicare patients. That's the conclusion of a new study by Harvard Medical School and Brigham and Women's Hospital. As the
Cancer care advances. So does the cost of treatment. U.S. spending on oncology drugs could grow by 10 percent per year through 2013, Medco Health Solutions has found, partly because patients are
Like many government health programs, the UK's National Health Service has been fighting budget shortfalls. Unlike private insurers, the NHS makes news whenever it cuts benefits. And unfortunately
Cancer care may cost the U.S. two-thirds more in the next decade, potentially topping $200 billion by 2020 as the population ages and drug prices continue to rise. Report
Coupons work. That's what drugmakers have discovered from the co-pay assistance they've been offering to shore up demand for aging branded drugs (Pfizer's statin Lipitor), create demand for new ones